FMI
Foundation Medicine, Inc.
Set alert
137.00 0.00 0.00%
137.00 Day range 137.00
136.75 52-week range 137.00
- Open
- 137.00
- Prev close
- 137.00
- Mkt cap
- 0
- Vol
- 0
- Avg vol
- 347.22K
- EPS
- -3.87
- P/E
- -35.39
- Div yield
- 0.00%
More statistics
- Low
- 137.00
- High
- 137.00
- Forward P/E
- 0.00
- Beta
- 0.00
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 7, 2018
- 50-d avg
- 0.00
- 200-d avg
- 0.00
Key statistics
- Market cap
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- Price / sales
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- 50-day average
- 0.00
- 200-day average
- 0.00
Next earnings
Aug 7, 2018
Expected Aug 7, 2018. Consensus EPS estimate 0.00.
Financials — quick view
FMI Revenue — quarterly 57.01M
FMI Net income — quarterly -33.38M
FMI EPS — quarterly -0.90
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 7, 2018 | Jun 1, 2018 | -1.12 | — | — | — |
| May 2, 2018 | Mar 1, 2018 | -1.13 | — | — | — |
| Mar 7, 2018 | Dec 1, 2017 | -1.01 | — | — | — |
| Nov 1, 2017 | Sep 1, 2017 | -1.07 | — | — | — |
| Aug 1, 2017 | Jun 1, 2017 | -1.08 | — | — | — |
| May 9, 2017 | Mar 1, 2017 | -1.02 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 14, 2018 | Cowen & Co. | init | — | Outperform |
| Jan 28, 2018 | Goldman Sachs | init | — | Neutral |
| May 14, 2017 | BTIG Research | up | — | Buy |
| Mar 6, 2017 | Janney Capital | up | — | Neutral |
| Nov 2, 2016 | Benchmark | down | — | Hold |
| Aug 2, 2016 | Janney Capital | down | — | Sell |
News
- Is Fastenal Co (FAST) Overvalued After Q3 Earnings Beat? EPS at $0.35 vs Estimated $0.34, Revenue at $2.463 Billion vs Estimated $2.440 Billion -- GF Score: 95/100
- Fastenal Co (FAST) Q1 2026 Earnings Call Highlights: Strong Sales Growth Amid Pricing Challenges
- Spirit Announces Sale of Fiber Materials Inc. (FMI) to Tex Tech Industries
- Spirit Announces Purchase Agreement with Tex Tech Industries for Intended Sale of Fiber Materials, Inc. (FMI)
- Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator
- Foundation Medicine Announces Timing for First Quarter 2018 Financial Results and Conference Call
- Foundation Medicine Announces Timing for Fourth Quarter and Year-End 2017 Financial Results and Conference Call
- FDA Approves Foundation Medicine’s FoundationOne CDx™, the First and Only Comprehensive Genomic Profiling Test for All Solid Tumors Incorporating Multiple Companion Diagnostics
- Foundation Medicine Announces Timing for Third Quarter 2017 Financial Results and Conference Call
- Foundation Medicine Announces Timing for Second Quarter 2017 Financial Results and Conference Call
Your note
Sign in to keep a note on FMI — it syncs with the Stock Master app.